Eda DOGAN, Zekeriya DUZGUN, Zafer YİLDİRİM, Berrin OZDİL, Huseyin AKTUG, Vildan BOZOK CETİNTAS

The effects of PIKfyve inhibitor YM201636 on claudins and malignancy potential of nonsmall cell cancer cells

PIKfyve is an evolutionarily conserved lipid and protein kinase enzyme that has pleiotropic cellular functions. The aim of the present study was to investigate the effects of phosphatidylinositol-3-phosphate 5-kinase (PIKfyve) inhibitor, YM201636, on nonsmall cell lung cancer (NSCLC) cells growth, tumorigenicity, and claudin (CLDN) expressions. Three NSCLC cell lines (Calu-1, H1299 and HCC827) were used to compare the effects of YM201636. Cytotoxic effects of YM201636 were analysed using XTT assay. Malignancy potential of cells assesses with wound healing and soft agar colony-forming assays. mRNA and protein expressions of claudins were analysed by qRT-PCR and immunofluorescence staining. Our results revealed that YM201636 inhibited the proliferation and malignancy potential of Calu-1, H1299, and HCC827 cells in a dose-dependent manner. After YM201636 treatment CLDN1, -3 and -5 expressions increased significantly in HCC827 cells. CLDN3 and -5 expressions also significantly increased in Calu-1 cell line. YM201636 treatment significantly reduced the CLDN1 and increased the CLDN5 expression in H1299 cells. Immunofluorescence staining of CLDN1, -3 and -5 proteins showed a significant increase after YM201636 treatment. Besides, YM201636 induced EGFR mRNA expression in all NSCLC cell lines. Our results have shown that YM201636 inhibits tumorigenicity of NSCLC cells. Furthermore, estimated glomerular filtration rate (EGFR) pathway is important signalling involved in the regulation of claudins. Understanding the mechanisms of PIKfyve inhibitors may improve cancer treatment particularly for EGFR overactivated NSCLC.

Keywords:

Claudin, epidermal growth factor receptor, nonsmall cell lung cancer, PIKfyve, YM201636,

PDF

___

de Campos CB, 2020, HAEMATOLOGICA, V105, P1641, DOI 10.3324/haematol.2019.222729
Dukes JD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0028659
Fang H, 2019, INT J MOL MED, V43, P1522, DOI 10.3892/ijmm.2018.4046
Hou JZ, 2019, ONCOL REP, V41, P1971, DOI 10.3892/or.2018.6928
Hung CY, 2014, BBA-MOL CELL RES, V1843, P2843, DOI 10.1016/j.bbamcr.2014.08.009
Ikonomov OC, 2006, AM J PHYSIOL-CELL PH, V291, pC393, DOI 10.1152/ajpcell.00019.2006
Ikonomov OC, 2018, TOXICOL APPL PHARM, V356, P151, DOI 10.1016/j.taap.2018.08.001
Jefferies HBJ, 2008, EMBO REP, V9, P164, DOI 10.1038/sj.embor.7401155
Khan N, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/219843
Kim H, 2020, BIOCHEM CELL BIOL, V98, P219, DOI 10.1139/bcb-2019-0139
Kim J, 2007, CANCER RES, V67, P9229, DOI 10.1158/0008-5472.CAN-07-1333
Krause G, 2009, ANN NY ACAD SCI, V1165, P34, DOI 10.1111/j.1749-6632.2009.04057.x
Ma L, 2019, LUNG CANCER MANAG, V8, DOI 10.2217/lmt-2018-0010
Martin S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060152
Martin TA, 2009, BBA-BIOMEMBRANES, V1788, P872, DOI 10.1016/j.bbamem.2008.11.005
McCartney AJ, 2014, P NATL ACAD SCI USA, V111, pE4896, DOI 10.1073/pnas.1411117111
Merikallio H, 2011, EUR J CANCER, V47, P620, DOI 10.1016/j.ejca.2010.10.017
Moldvay J, 2007, LUNG CANCER, V57, P159, DOI 10.1016/j.lungcan.2007.02.018
Moldvay J, 2017, PATHOL ONCOL RES, V23, P151, DOI 10.1007/s12253-016-0115-0
Oppelt A, 2014, BIOCHEM J, V461, P383, DOI 10.1042/BJ20140132
Oppelt A, 2013, EMBO REP, V14, P57, DOI 10.1038/embor.2012.183
Salvador Ellaine, 2016, Curr Pathobiol Rep, V4, P135
Sbrissa D, 2004, ENDOCRINOLOGY, V145, P4853, DOI 10.1210/en.2004-0489
Sbrissa D, 2007, J BIOL CHEM, V282, P23878, DOI 10.1074/jbc.M611678200
Shin K, 2006, ANNU REV CELL DEV BI, V22, P207, DOI 10.1146/annurev.cellbio.22.010305.104219
Shisheva A, 2001, CELL BIOL INT, V25, P1201, DOI 10.1006/cbir.2001.0803
Shisheva A, 2008, CELL BIOL INT, V32, P591, DOI 10.1016/j.cellbi.2008.01.006
Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI 10.3322/caac.21332
Singh AB, 2004, J BIOL CHEM, V279, P3543, DOI 10.1074/jbc.M308682200
Soini Y, 2011, RESP RES, V12, DOI 10.1186/1465-9921-12-70
Sun BS, 2016, THORAC CANCER, V7, P556, DOI 10.1111/1759-7714.12368
Tan XJ, 2015, CELL, V160, P145, DOI 10.1016/j.cell.2014.12.006
Zhang LM, 2017, ONCOTARGET, V8, P23033, DOI 10.18632/oncotarget.14974